
Diagnostic and therapeutic advances in genetic neuromuscular diseases


S H Subramony M.D.

Professor of Neurology and Pediatrics University of Florida College of Medicine and Fixel Institute for Neurological Disorders



Genetic testing in neuromuscular disease


- Reasons for genetic testing
- Picking the right test
 - Disorders not detected by sequencing panels; repeat expansions, large deletions, duplications
 - Usually have recognizable phenotype: Duchenne, myotonic dystrophy, facioscapulohumeral dystrophy, Friedreich ataxia, CMT type 1, HNPP, C9Orf72 ALS, Kennedy's, OPMD
- "Limb girdle" and other atypical presentations need sequencing panels that assess several genes
 - Actionable items
 - VUS interpretation



Nature Reviews | Neurology


SMA: Gene therapy

- Onasemnogene abeparvovec: AAV 9 based gene replacement delivered by a single IV injection
- START, STRIVE and SPRINT trials in SMA infants >6 mos, < 6 mos and presymptomatic
- All survived for > 5 years with no vent support and improved motor milestones
- Approved for 5q SMA < 2 years (FDA); SMA type 1 up to 3 SMN 2 copies and weight <21 Kg (EMA)
- Dose 1.1 X 10E14 vg/kg, IV over 60 minutes, steroids
- AEs: elevated LFT, vomiting, platelet issues



а


Mondol	2017
Mendel	



Gowda 2023

	2.2	CHOP-INTEND		Mean difference	%	
	Reference	Basal		(95% CI)	Weight	
	CHOP INTEND - 3 months					-
	Day JW et al (2021)	32.0		11.70 (9.03, 14.37)	35.34	
	Mendell JR et al (2017)	28.2		15.40 (6.27, 24.53)	3.03	
	Mercuri E et al (2021)	27.9		10.30 (8.05, 12.55)	49.73	
	Strauss KA et al (2022)	46.1		11.20 (6.59, 15.81)	11.90	
	Subtotal (I-squared = 0.0%, p = 0.676)		\diamond	11.06 (9.47, 12.65)	100.00	
	CHOP INTEND - 6 months					
	Day JW et al (2021)	32.0		14.60 (11.66, 17.54)	34.14	
	Mercuri E et al (2021)	27.9		13.60 (11.16, 16.04)	49.44	
	Strauss KA et al (2022)	46.1		14.80 (10.56, 19.04)	16.41	
	Subtotal (I-squared = 0.0%, p = 0.829)		\diamond	14.14 (12.42, 15.86)	100.00	
_						-
		-12.5 0.0	12.5	25.0		

Pascual-Morena 2023



Strauss 2022

SMA: splice modulation

		Adults		
A	Source	Results	N, Age	Baseline
Treated cohorts	Jochmann et al. 2020 [15] Maggi et al. 2020 [16] Hagenacker et al. 2020 [17] Maggi et al. 2021 [27] Hagenacker et al. 2020 [17] Maggi et al. 2021 [27] Hagenacker et al. 2020 [16] Ambulant Hagenacker et al. 2020 [17] Ambulant Walter et al. 2020 [17] Maggi et al. 2020 [17] Maggi et al. 2020 [16] Ambulant Non ambulant Pera et al. 2021 [29] Maggi et al. 2020 [16] Ambulant Non ambulant Hagenacker et al. 2020 [17] Ambulant Non ambulant Hagenacker et al. 2020 [17] Ambulant Non ambulant Hagenacker et al. 2020 [27] Yeo et al. 2021 [27] Yeo et al. 2021 [28] Mendonça et al. 2021 [28] Osmanovic et al. 2020 [21] De Wel et al. 2020 [22]		$\begin{array}{rrrr} n=3 & 34.3 (22.50) \\ n=9 & 24.0 (19.41)* \\ n=30 & 37.0 (16.5)** \\ n=5 & 24.0 (19.41)* \\ n=11 & 33.7 (17.66)** \\ n=20 & 33.0 (16.59)** \\ n=75 & Nor reported \\ n=40 & 33.0 (18.68)* \\ n=35 & 40.0 (18.72)* \\ n=60 & 37.0 (16.65)** \\ n=35 & 7.5 (18.50) \\ n=3 & 44.3 (20.68) \\ n=46 & Nor reported \\ n=27 & 33.0 (18.68)* \\ n=19 & 40.0 (18.72)* \\ n=19 & 40.0 (18.72)* \\ n=19 & 35.8 (20.68) \\ n=19 & 35.8 (20.68) \\ n=19 & 35.8 (20.68) \\ n=26 & 40.0 (20.58) \\ n=27 & 33.0 (16.59)** \\ n=20 & 33.7 (17.66)** \\ n=6 & 29.9 (24.56) \\ n=4 & 33.0 (26.42) \\ n=24 & 37.9 (19.64) \\ n=16 & 37.5 (22.66) \\ \end{array}$	0.7 (0-2) 0.0 (0-9)* 22.9 (+21.7)*** 0.0 (0-9)* 19.0 (0-60)** 24.6 (+21.8) Not reported 50.5 (17-64)* 9.0 (0-40)* 22.9 (+21.7)** Not reported 35.2 (0-64)* 26.8 (6-56) 31.7 (6-60) Not reported 50.5 (17-64)* 9.0 (0-40)* 30.1 (0-61) 46.9 (23-61) 17.8 (0-43) 24.6 (+21.8)** Not reported 19.0 (0-60)** 35.0 (21-53) 16.8 (3-44) 23.2 (0-64) 27.3 (+19.8)
Untreated cohorts	Coratti et al. 2020 (165) Wijngaarde et al. 2020 (169) 2b 3a 3b Coratti et al. 2020 (15) Non ambulant Ambulant Wadman et al. 2018 (189)		$\begin{array}{llllllllllllllllllllllllllllllllllll$	3.21 (0-24) Not reported Not reported Not reported 30.4 (6-62) 17.9 (6-33) 51.94 (38-62) Not reported

Nusinersen: ASO that modulates SMA 2 splicing

- Trials in early and late onset SMA with significant survival with no vent support and achievement of motor milestones
- Continued stability in OLE
- Effective with presymptomatic delivery
- IT delivery, monitor coag function and renal function
- Risdiplam, oral molecule that modulates SMN 2 splicing
 - Trials showing similar results
 - Oral delivery
- Both approved for all ages

	Pediatrics			
B	Source	Results	N, Age	Baseline
Treated cohorts	Mendonça et al. 2021 [26] Mendonça et al. 2021 [26] Szabò et al. 2020 [11] Coratti et al. 2021 [16] Mendonça et al. 2021 [26] Mendonça et al. 2021 [26] Pera et al. 2021 [26] Mon ambulant Szabò et al. 2020 [16] Mendonça et al. 2021 [26] Mendonça et al. 2021 [26]		$\begin{array}{rrrr} n\!=\!14 & 10.6 \;(+10.3)^{*} \\ n\!=\!14 & 10.6 \;(+10.3)^{*} \\ n\!=\!16 & 4.5 \;(+3.3)^{*} \\ n\!=\!77 & 7.5 \;(2{\text{-}}17) \\ n\!=\!16 & 10.6 \;(+10.3)^{*} \\ n\!=\!59 & 9.5 \;(2{\text{-}}5{\text{-}}7{\text{-}}9) \\ n\!=\!16 & 10.6 \;(+10.3)^{*} \\ n\!=\!18 & 10.8 \;(2{\text{-}}5{\text{-}}7{\text{-}}9) \\ n\!=\!18 & 10.8 \;(2{\text{-}}5{\text{-}}7{\text{-}}9) \\ n\!=\!18 & 10.8 \;(2{\text{-}}5{\text{-}}7{\text{-}}9) \\ n\!=\!30 & 10.6 \;(+10.3) \\ n\!=\!30 & 10.6 \;(+10.3) \end{array}$	Not reported Not reported 21.2 (+6.5) 10.3 (0-39) Not reported Not reported 43.22 (6-66) 52.9 (37-66) 21.2 (6-32) Not reported 25.4 (+17.2) 25.4 (+17.2)
Untreated cohorts	Mendonça et al. 2021 (26) Mendonça et al. 2021 (26) Coratti et al. 2020 (26) Mendonça et al. 2021 (26) Mendonça et al. 2021 (26) Coratti et al. 2020 (26) Ambulant Non ambulant Mendonça et al. 2021 (26) Mendonça et al. 2021 (26)		$\begin{array}{rrrr} n=20 & 10.2 \ (+5.6)^{*} \\ n=20 & 10.2 \ (+5.6)^{*} \\ n=589 & 7.83 \ (2.4.17.5) \\ n=283 & 7.47 \ (2.4.17.6) \\ n=17 & 10.2 \ (+5.6)^{*} \\ n=17 & 10.2 \ (+5.6)^{*} \\ n=371 & 9.4 \ (2.5.17.9) \\ n=53 & 8.9 \ (2.5.17.9) \\ n=54 & 11.6 \ (3.0.16.9) \\ n=37 & 10.2 \ (+5.6) \end{array}$	Not reported Not reported 12.55 (9-41) 13.1 (0-36) Not reported 48.2 (4-66) 29.4 (4-57) 24.9 (+18.0) 24.9 (+18.0)

SMA Best Practice guidelines (Neurology Clinical Practice 2024)

- Diagnosis: For symptomatic SMA patients need to follow standard process, based on clinical scenario, most have homozygous deletions of exon 7/8, assess SMN 2 copy number
- SMA new-born screening is essential but is in varied stages of development across the world; often uses qPCR multiplexed to SCID testing
- SMA diagnosed by NBS requires SMN 2 copy number estimation, current motor function, age at onset and severity
- US consensus: urgent treatment needed for all including SMN copy number of 4
- Estimation of current motor function essential, better motor function leads to better response but may be difficult to distinguish symptomatic vs presymptomatic
- Age at symptoms onset and severity of symptoms influences response

- Requirements for NBS: how to notify family and coordinate initial visit, process to prevent delays in treatment, process to refer to SMA specialists, collaborative team, efficient process for approval
- Requirements for NBS testing labs
- Requirements for SMA SCCs: prompt evaluations, confirmatory testing, other necessary labs (nAbs, LFT etc) education and resources for care givers, coordination with team and primary care providers

Duchenne muscular dystrophy



Exon skipping

Splice switching ASOs that restore reading frame

Eteplirsen (exon 51), Golodirsen, Viltolarsen (exon 53) and Casimersen (exon 45)

Accelerated approval based on increased dystrophin expression from 0.9% to 5.8%

Need for further confirmation

Long term follow up and comparison to natural history cohorts show potential for continued benefit



Givinostat

HDAC inhibitor targeting global HDAC activation in DMD

Single trial with improvement in primary outcome measure (4 step climb; decline of 1.25 vs 3.03 sec)

Monitor platelets and triglycerides





Vamolorone

Dissociative corticosteroid with fewer bone effects

DMD Gene therapy


- Delandistrogene moxeparvovec, AAVrh74 based delivery of microdystrophin
- Accelerated approval in June 2023 based on dystrophin expression in muscle after delivery to ambulatory boys 4 to 8 yrs, 54.2% after 12 weeks.
- Dose 1.33 X 10E14 vg/Kg, single IV administration
- Contraindicated with exon 8 and/or 9 deletion and elevated Ab to AAVrh74
- Concern for liver, muscle and myocardial toxicity
- AEs include vomiting, poor appetite, URIs, nausea, limb and abdominal pain
- EMBARK; phase 3, RCT (2024) did not meet primary outcome measure at week 52 but secondary endpoints favored treatment
- Traditional approval in 2024 for ambulatory DMD > 4 years and accelerated for non-ambulatory > 4 years







Omaveloxolone in Friedreich ataxia

- Activates impaired oxidative defense pathway mediated by Nrf 2
- RCT shows significant benefit in neurological function based on mFARS scale
- Added support from delayed start analysis and propensity matched analysis
- Tolerated well but LFT elevation was common











Myotonic dystrophy 1

- Toxic gain of function of DMPK mRNA
- Sequesters MBNL
- Strategy: knockdown of mRNA using antibody conjugated shRNA (Avidity)









Facioscapulohumeral dystrophy

- Mutation causes aberrant expression of DUX 4
- DUX 4 drives myopathology
- Strategy: knockdown of DUX 4 mRNA using antibody conjugated shRNA

